Terminated PHASE3 INTERVENTIONAL 1-arm NCT00607256

Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia

A Multi-center, Long-term, Open-label Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia

Sponsor: Pfizer

Conditions Fibromyalgia

Interventions [S,S]-reboxetine

Updated 9 times since 2017 Last updated: Dec 11, 2019 Started: Oct 20, 2007 Primary completion: May 18, 2009 Completion: May 18, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Pfizer

See all terminations from Pfizer

Other Fibromyalgia trials with similar outcome

Browse all Fibromyalgia trials

Listed as NCT00607256, this PHASE3 trial focuses on Fibromyalgia and remains terminated or withdrawn. Sponsored by Pfizer, it has been updated 9 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE3

▶ Show 4 earlier versions

Jan 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2020 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anderson, United States , Berlin, Germany , Bethlehem, United States , Boksburg, South Africa , Breda, Netherlands , Brussels, Belgium , Cambridge, United Kingdom , Cary, United States , Charleston, United States , Cincinnati, United States and 64 more locations